GSK Plc is pushing the UK government to give pharmaceutical companies more access to its public health data troves, to ...

Compelling preclinical data in models of both GBA1-PD and idiopathic PD, demonstrating a disease-modifying effect after administration of GT-02287, suggest that GT-02287 may have the potential to slow ...

Drug development programs face unique challenges in demonstrating the safety and effectiveness of drugs for treating rare diseases. The ...

Cell membrane proteins hide secret gateways that can be used to modify cell behavior. This has been demonstrated in a study ...

GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.8 at the end of 2024 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...